• Je něco špatně v tomto záznamu ?

Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy

A. Vallès, MM. Evers, A. Stam, M. Sogorb-Gonzalez, C. Brouwers, C. Vendrell-Tornero, S. Acar-Broekmans, L. Paerels, J. Klima, B. Bohuslavova, R. Pintauro, V. Fodale, A. Bresciani, R. Liscak, D. Urgosik, Z. Starek, M. Crha, B. Blits, H. Petry, Z....

. 2021 ; 13 (588) : . [pub] 20210407

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025864

Huntingtin (HTT)-lowering therapies hold promise to slow down neurodegeneration in Huntington's disease (HD). Here, we assessed the translatability and long-term durability of recombinant adeno-associated viral vector serotype 5 expressing a microRNA targeting human HTT (rAAV5-miHTT) administered by magnetic resonance imaging-guided convention-enhanced delivery in transgenic HD minipigs. rAAV5-miHTT (1.2 × 1013 vector genome (VG) copies per brain) was successfully administered into the striatum (bilaterally in caudate and putamen), using age-matched untreated animals as controls. Widespread brain biodistribution of vector DNA was observed, with the highest concentration in target (striatal) regions, thalamus, and cortical regions. Vector DNA presence and transgene expression were similar at 6 and 12 months after administration. Expression of miHTT strongly correlated with vector DNA, with a corresponding reduction of mutant HTT (mHTT) protein of more than 75% in injected areas, and 30 to 50% lowering in distal regions. Translational pharmacokinetic and pharmacodynamic measures in cerebrospinal fluid (CSF) were largely in line with the effects observed in the brain. CSF miHTT expression was detected up to 12 months, with CSF mHTT protein lowering of 25 to 30% at 6 and 12 months after dosing. This study demonstrates widespread biodistribution, strong and durable efficiency of rAAV5-miHTT in disease-relevant regions in a large brain, and the potential of using CSF analysis to determine vector expression and efficacy in the clinic.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025864
003      
CZ-PrNML
005      
20211026133433.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1126/scitranslmed.abb8920 $2 doi
035    __
$a (PubMed)33827977
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vallès, Astrid $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands. a.vallessanchez@uniqure.com m.evers@uniqure.com
245    10
$a Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy / $c A. Vallès, MM. Evers, A. Stam, M. Sogorb-Gonzalez, C. Brouwers, C. Vendrell-Tornero, S. Acar-Broekmans, L. Paerels, J. Klima, B. Bohuslavova, R. Pintauro, V. Fodale, A. Bresciani, R. Liscak, D. Urgosik, Z. Starek, M. Crha, B. Blits, H. Petry, Z. Ellederova, J. Motlik, S. van Deventer, P. Konstantinova
520    9_
$a Huntingtin (HTT)-lowering therapies hold promise to slow down neurodegeneration in Huntington's disease (HD). Here, we assessed the translatability and long-term durability of recombinant adeno-associated viral vector serotype 5 expressing a microRNA targeting human HTT (rAAV5-miHTT) administered by magnetic resonance imaging-guided convention-enhanced delivery in transgenic HD minipigs. rAAV5-miHTT (1.2 × 1013 vector genome (VG) copies per brain) was successfully administered into the striatum (bilaterally in caudate and putamen), using age-matched untreated animals as controls. Widespread brain biodistribution of vector DNA was observed, with the highest concentration in target (striatal) regions, thalamus, and cortical regions. Vector DNA presence and transgene expression were similar at 6 and 12 months after administration. Expression of miHTT strongly correlated with vector DNA, with a corresponding reduction of mutant HTT (mHTT) protein of more than 75% in injected areas, and 30 to 50% lowering in distal regions. Translational pharmacokinetic and pharmacodynamic measures in cerebrospinal fluid (CSF) were largely in line with the effects observed in the brain. CSF miHTT expression was detected up to 12 months, with CSF mHTT protein lowering of 25 to 30% at 6 and 12 months after dosing. This study demonstrates widespread biodistribution, strong and durable efficiency of rAAV5-miHTT in disease-relevant regions in a large brain, and the potential of using CSF analysis to determine vector expression and efficacy in the clinic.
650    _2
$a zvířata $7 D000818
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a genetická terapie $7 D015316
650    _2
$a genetické vektory $x genetika $7 D005822
650    _2
$a lidé $7 D006801
650    _2
$a protein huntingtin $x genetika $x metabolismus $7 D000071058
650    12
$a Huntingtonova nemoc $x genetika $x terapie $7 D006816
650    12
$a mikro RNA $x metabolismus $7 D035683
650    _2
$a prasata $7 D013552
650    _2
$a miniaturní prasata $x metabolismus $7 D013556
650    _2
$a tkáňová distribuce $7 D014018
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Evers, Melvin M $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands. a.vallessanchez@uniqure.com m.evers@uniqure.com
700    1_
$a Stam, Anouk $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Sogorb-Gonzalez, Marina $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Brouwers, Cynthia $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Vendrell-Tornero, Carlos $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Acar-Broekmans, Seyda $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Paerels, Lieke $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Klima, Jiri $u Institute of Animal Physiology and Genetics, Rumburská 89, 277 21 Libechov, Czech Republic
700    1_
$a Bohuslavova, Bozena $u Institute of Animal Physiology and Genetics, Rumburská 89, 277 21 Libechov, Czech Republic
700    1_
$a Pintauro, Roberta $u Department of Translational Biology, IRBM Science Park S.p.A., Via Pontina km 30,600, 00071 Pomezia, Italy
700    1_
$a Fodale, Valentina $u Department of Translational Biology, IRBM Science Park S.p.A., Via Pontina km 30,600, 00071 Pomezia, Italy
700    1_
$a Bresciani, Alberto $u Department of Translational Biology, IRBM Science Park S.p.A., Via Pontina km 30,600, 00071 Pomezia, Italy
700    1_
$a Liscak, Roman $u Department of Stereotactic Radioneurosurgery, Na Homolce Hospital, Roentgenova 37/2, 150 30, Prague 5, Czech Republic
700    1_
$a Urgosik, Dusan $u Department of Stereotactic Radioneurosurgery, Na Homolce Hospital, Roentgenova 37/2, 150 30, Prague 5, Czech Republic
700    1_
$a Starek, Zdenek $u Interventional Cardiac Electrophysiology, St. Anne's University Hospital, Pekařská 53, 656 91 Brno, Czech Republic
700    1_
$a Crha, Michal $u Small Animal Clinic, Veterinary and Pharmaceutical University, Palackého třída 1946/1, 612 42 Brno, Czech Republic
700    1_
$a Blits, Bas $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Petry, Harald $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Ellederova, Zdenka $u Institute of Animal Physiology and Genetics, Rumburská 89, 277 21 Libechov, Czech Republic
700    1_
$a Motlik, Jan $u Institute of Animal Physiology and Genetics, Rumburská 89, 277 21 Libechov, Czech Republic
700    1_
$a van Deventer, Sander $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
700    1_
$a Konstantinova, Pavlina $u Department of Research and Development, uniQure biopharma B.V., Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands
773    0_
$w MED00177505 $t Science translational medicine $x 1946-6242 $g Roč. 13, č. 588 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33827977 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133439 $b ABA008
999    __
$a ok $b bmc $g 1714769 $s 1146371
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 588 $e 20210407 $i 1946-6242 $m Science translational medicine $n Sci Transl Med $x MED00177505
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace